Moderna stock returns to profit as 2026 outlook rises

Published on 11/10/2026 at 13:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock follows a return to quarterly profit and a stronger 2026 revenue outlook. New vaccine and oncology progress add pipeline support.

Profitability and guidance improve

Moderna returned to quarterly GAAP profitability in the third quarter of 2026.
Management raised its full-year revenue growth outlook to 15% to 25%.
New vaccine approval and positive melanoma data added pipeline support.

Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Moderna reported a return to quarterly profitability in the third quarter of 2026 and raised its full-year revenue outlook, according to the company's Q3 2026 results published on November 6. The biotechnology company said revenue increased 29% year over year to USD 1.3 billion, while GAAP net income reached USD 0.2 billion and diluted earnings per share were USD 0.38.

International demand drives the quarter

Moderna attributed the revenue increase mainly to higher COVID-19 vaccine sales in international markets and deliveries under long-term government partnerships. The company also highlighted continued commercial momentum as the seasonal vaccination period progressed.

The return to profit marks a sharp improvement from the year-earlier quarter, when Moderna reported a GAAP net loss. Cost control also remains central to the recovery plan. Management said the 2026 operating expense outlook improved by approximately USD 0.2 billion from its previous estimate.

Management raises the 2026 framework

Moderna now expects total revenue growth of 15% to 25% in 2026, compared with its previous outlook for growth of up to 10%. The company also raised its expected year-end cash and investments to USD 8.1 billion to USD 8.3 billion.

The outlook gives investors a clearer test for the company's recovery beyond COVID-19 vaccine demand. Higher international sales can support near-term revenue, while lower spending and a stronger cash position may give Moderna more flexibility to fund its pipeline. The forecast still depends on seasonal vaccine demand and the timing of product deliveries.

Pipeline adds another investor focus

Alongside the financial update, Moderna highlighted positive Phase 3 data for intismeran in melanoma and U.S. Food and Drug Administration approval of mFLUSIVA. The company described mFLUSIVA as its fifth approved product globally. These developments broaden the focus beyond the established COVID-19 franchise, although commercial execution will determine how quickly they contribute to growth.

Moderna stock traded at 240.78 euros on Lang & Schwarz at 13:48 CET on Tuesday, November 10.